| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA   |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
The Motley Fool
December 19, 2005
Brian Gorman |
Developing Drug Markets Drug companies focusing on the developing world could see major payoffs. Asia, Africa, and Australia offer very significant opportunities for investors. |
Chemistry World
August 5, 2015
Emma Stoye |
Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
Chemistry World
January 19, 2015
Maria Burke |
Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
American Family Physician
May 15, 2001 |
Pneumococcal Conjugate Vaccine: What a Parent Needs to Know Why should my child get this vaccine?... What exactly is the pneumococcal vaccine?... Are there some children who should not get pneumococcal conjugate vaccine or who should wait until they are older?... |
Chemistry World
September 3, 2009
Sarah Houlton |
New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine. |
The Motley Fool
December 13, 2007
Brian Orelli |
Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections. |
Chemistry World
October 23, 2014
Rebecca Trager |
US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
The Motley Fool
December 30, 2008
Brian Orelli |
A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus. |
Chemistry World
December 3, 2014
Maria Burke |
Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Pharmaceutical Executive
June 1, 2005
Sibyl Shalo |
Chief of Staph Nabi, a small pharmaceutical company, has found a way to make money by making vaccines. Nabi now aims to become the first company to market a vaccine to attack the deadly staph bacterium. |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
The Motley Fool
March 18, 2008
Brian Orelli |
Dynavax Gets Held Up The FDA puts a clinical hold on Dynavax Technologies hepatitis B vaccine. Investors, take note. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
The Motley Fool
August 21, 2009
Brian Orelli |
Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend. |
American Family Physician
July 15, 2003
Sur et al. |
Vaccinations in Pregnancy Routine vaccines that generally are safe to administer during pregnancy include diphtheria, tetanus, influenza, and hepatitis B. Other vaccines, such as meningococcal and rabies, may be considered. |
Pharmaceutical Executive
October 1, 2014
Jill Wechsler |
Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak. |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
American Family Physician
July 1, 2004
Lo Re & Gluckman |
Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
BusinessWeek
April 12, 2004
Catherine Arnst |
Killer Staph Is Hitting The Streets For the past 30 years, hospitals have been battling a mutant form called methicillin-resistant S. aureus (MRSA) that is resistant to penicillin-related antibiotics and is especially lethal. Now it's showing up in the general population. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
American Family Physician
December 1, 2002
Sanford R. Kimmel |
Vaccine Adverse Events: Separating Myth from Reality Vaccines have turned many childhood diseases into distant memories in industrialized countries. However, questions have been raised about the safety of some vaccines because of rare but serious adverse effects that have been attributed to them. |
AskMen.com
Dustin Driver |
Travel Diseases: Central & South America There are more than a few diseases that can turn your dream vacation to Central or South America into a nightmare -- so here are a few "ounces of prevention." |
Chemistry World
January 16, 2011
Hayley Birch |
Antibodies could lead to MRSA vaccine US scientists have developed antibodies against a protein belonging to methicillin-resistant Staphylococcus aureus bacteria. |
Chemistry World
April 2008
Victoria Gill |
Malaria no More? A fresh round of research funding could put an end to the killer disease. |
Pharmaceutical Executive
February 1, 2007
Joanna Breitstein |
Net Effect Ripley Ballou may finally win approval for a vaccine he started testing as an army physician more than 25 years ago - an advance that could mark the beginning of a whole new phase in the battle against one of the world's great killers: malaria. |
Chemistry World
February 7, 2008
Hepeng Jia |
Profile: Vaccine Trailblazer Yin Weidong is one of the leading lights of China's fast growing biotech industry and Sinovac the first Chinese biotech firm listed on the US stock exchange. |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
Chemistry World
February 9, 2007
Victoria Gill |
Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo. |
American Family Physician
May 15, 2001
Richard Kent Zimmerman |
Pneumococcal Conjugate Vaccine for Young Children Pneumococcal conjugate vaccine, approved in 2000 for use in the United States, was designed to cover the seven serotypes that account for about 80 percent of invasive infections in children younger than six years... |
Chemistry World
February 2006 |
Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development. |
Chemistry World
December 21, 2015
Jennifer Newton |
Mexico approves world's first dengue vaccine Dengvaxia from Sanofi's vaccines division, Sanofi Pasteur, protects against all four dengue virus serotypes and will be aimed at residents in endemic areas aged nine to 45. |
The Motley Fool
September 19, 2007
Billy Fisher |
Prevnar Problems at Wyeth? New strains of bacteria might make the popular pneumonia vaccine less effective. While Prevnar might come under siege from superbugs, one doubts that Wyeth's stock price will become similarly cure-resistant. |
The Motley Fool
May 10, 2011
Brian Orelli |
Pfizer's Multibillion-Dollar Blockbuster Set to Grow Pfizer will make money off old people, too. |
